We’re Months Away From Bankruptcies in the Cannabis Sector

Learn about risks in the cannabis sector by looking at Aurora Cannabis (TSX:ACB)(NYSE:ACB) as a case study.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

In early 2019, if someone were to suggest that by the end of 2020, we’d start seeing bankruptcies in Canada’s cannabis sector, you would most certainly have concluded they were smoking something.

Here we are a year later, and these concerns don’t seem so far-fetched. Cannabis companies have exhibited a general lack of fiscal prudence over the past year. Examples include paying ridiculous (mostly paper) premiums to acquire each other in a frenzy that seemed worse than the dot-com bubble, in hindsight.

Aurora Cannabis

In this article, I’m going to use Aurora Cannabis (TSX:ACB)(NYSE:ACB) as an example to show just how close we are to seeing bankruptcies materialize in this sector (or at least a tonne of acquisitions at discounts instead of premiums).

Aurora was one of the companies I’ve identified in the past as being ridiculously valued. At one point, Aurora topped 135 times sales — a mind-blowing valuation. Today, the company is worth approximately $800 million with annualized sales of $247.9 million. This means Aurora is now priced around 3.5 times revenue. While still ridiculously high, it’s not outrageous.

We’re still years away from classifying this stock as “cheap,” but it is nice to see that financial markets seem to have regained some semblance of sanity of late. Stock prices across the cannabis sector are down in the 70-90% range from peaks for most producers over the past year. This reality makes it much harder for cannabis companies to raise billions of dollars in equity, as they were previously able to do. Aurora Cannabis is now worth “only” $800 million. That means the most this company could look to raise in equity markets is a few hundred million, before dilution would absolutely wreck existing shareholders.

A smoking load of debt

The problem is, Aurora has $1.4 billion in debt due over the next five years, making a couple hundred million seem petty. This debt was taken on to fund capital projects, which are still a long ways from producing profit in any meaningful amount. This means Aurora will likely be forced to refinance this debt down the road at much higher interest rates.

The company is also burning through a tonne of cash. Aurora will also likely need to raise more debt to fund its contractual obligations, which will not go away. Aurora, like most cannabis producers, has announced plans to cut capital expenditures for fear of incurring too much debt in the near term. But without a meaningful “real” stream of cash flow, any “profit” shown by the company is paper profit; this relates to ridiculous accounting rules that allow cannabis producers to book the value of the plants they grow before they are sold. This debt will become unrecoverable, and write-offs will ensue, with bankruptcies taking hold of the sector as a whole.

I’m not suggesting such a situation is imminent for Aurora, or any cannabis producer in particular right now. However, I believe that smaller producers that do not have similar access that Aurora has to capital markets will begin to go bankrupt before the end of this year. Trade carefully.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald does not have ownership in any stocks mentioned in this article.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »